Macrolide-resistant Streptococcus pneumoniae emerged in Argentina in 1995, representing 26% of invasive infection isolates in children under 5 years old. The objectives of this study were to describe the prevalence of ermB and mefA genes in macrolide-resistant S. pneumoniae isolates from acute otitis media (AOM) and to determine their genetic relatedness. Between May 2009 and August 2010, 126 S. pneumoniae isolates from 324 otherwise healthy children with a fi rst episode of AOM were included. Twenty six of these isolates (20.6%) were resistant to erythromycin. Most frequent serotypes were: 14 (46.2%), 6A (23.1%), 19F (7.7%) and 9V (7.7%). Twenty (76.9%) carried the mefA gene, 5 (19.2%) have the ermB gene, and 1 (3.9%) both ermB + mefA. Ten clonal types were identifi ed, mostly related to Sweden 15A -25/ST782 (SLV63), CloneB 6A /ST473 and England 14 -9/ ST9. This is the fi rst study assessing the mechanisms of macrolide resistance in pneumococci isolates from pediatric AOM in Argentina and their genetic relatedness.
Acute otitis media (AOM) is by far the most common disease caused by Streptococcus pneumoniae and one of the most frequent diagnoses in children under 2 years old. One out of every three children has at least one episode of AOM during the fi rst three years of life 1 . Over the last years, resistance to penicillin in S. pneumoniae has increased in Latin America and worldwide 10, 11 . Consequently, macrolides were used as initial empiric therapy for community-acquired respiratory tract infections 11 . Unfortunately, resistance to macrolides in S. pneumoniae has also evolved rapidly and in many countries the rate of S. pneumoniae resistant to macrolides exceeded the level of resistance to penicillin 2, 8 . Results from a global international surveillance project (PROTEKT, 1993 (PROTEKT, -2003 showed an increase in macrolide resistance from 31% in 1999 to 36.3% in 2003 11 . Macrolide resistance in S. pneumoniae causing infectious diseases in pediatric patients emerged in Argentina in 1995 and fi rstly increased to 1.4% between 1995-1997 and later to 6% in the period 1998-2001 6 . Nowadays, according to the Argentinian SIREVA II surveillance data, macrolide resistance reached 30.2% in 2011 10 . Four different mechanisms of resistance to macrolides have been described: antibiotic effl ux, mediated by mefA gene; target-site modifi cation by methylation of 23S rRNA due to erm genes; mutations in riboproteins L4 or L22 and mutations in domain II or V of 23S rRNA. The mefA gene, displaying an M-phenotype, has been associated with resistance to 14-and 15-membered macrolides. The ermB gene is known to confer cross-resistance to macrolides, lincosamides and streptogramins B, yielding the MLS Bphenotype 9 . The objectives of the present study were to determine the frequency of macrolide-resistant S. pneumoniae isolates from AOM, the prevalence of ermB (ribosomal methylase) and mefA (effl ux pump) genes and to determine their genetic relatedness.
Between May 2009 and August 2010, 324 immunocompetent children under 120 months (median age: 8 months) with a fi rst episode of AOM with purulent exudates in the middle ear were included in this study. Immunocompromised patients and those with chronic otitis media were excluded. All middle ear specimens obtained through tympanocentesis were cultured under standard conditions 7 . One hundred and thirty three pneumococci were isolated from 324 children suffering from AOM (41%), but 126 were available for this study.
Pneumococcal strains were serotyped by the Neufeld Quellung reaction using antiserum from the Statens Serum Institut, Copenhagen, Denmark.
Minimal inhibitory concentrations (MIC) were determined by the agar dilution method using Mueller Hinton agar (Difco, BD, USA) supplemented with 5% sheep blood and incubated overnight at 35 °C. MIC values of penicillin, amoxicillin, cefotaxime, erythromycin and clindamycin were interpreted according to Clinical and Laboratory Standards Institute recommendations. Susceptibility to chloramphenicol, tetracycline, ofl oxacin, vancomycin and trimethoprim-sulfamethoxazole was tested by the disk diffusion method according to the CLSI guidelines. Phenotypic characterization of macrolide resistance was performed by the double-disk diffusion method (D test), using disks of erythromycin (15 μg) and clindamycin (2 μg) to discriminate isolates expressing the M-and MLS Bphenotype (inducible or constitutive). MICs were interpreted according to the CLSI guidelines 5 . PCR assays for detection of mefA and ermB genes and pulse-fi eld gel electrophoresis (PFGE) were performed as previously described (6) . PFGE patterns were categorized using the Tenover criteria 14 and compared to international clones (http://www.sph.emory.edu/PMEN/). Multilocus sequence typing (MLST) was carried out as previously described, with fi ve selected strains of each dominant PFGE pattern and those associated with international clones (www.mlst.net/).
Twenty six of the 126 available pneumococci (20.6%) were classifi ed as erythromycin-resistant and were further studied. Although macrolide resistance in our country has been increasing steadily since 1995 10 , these resistance
Resistencia a macrólidos en Streptococcus pneumoniae aislados de pacientes pediátricos con otitis media aguda en la Argentina
Resumen Streptococcus pneumoniae resistente a macrólidos emergió en la Argentina en 1995 y representa el 26 % de los aislamientos de infecciones invasivas en niños menores de 5 años. El objetivo de este trabajo fue describir la prevalencia de ermB y mefA en neumococos resistentes a macrólidos aislados de niños con otitis media aguda (OMA) y determinar su relación genética. En 15 meses se incluyeron 126 neumococos aislados de 324 niños previamente sanos, con un primer episodio de OMA. Veintiseis (20,6 %) eran resistentes a eritromicina. Los serotipos más frecuentes fueron los siguientes: 14 (46,2 %), 6A (23,1 %), 19F (7,7 %) y 9V (7,7 %). Veinte eran portadores del gen mefA, 5 del gen ermB y el restante portaba ambos genes. Se identifi caron 10 tipos clonales, la mayoría relacionados con los clones Sweden 15A -25/ST782 (SLV63), CloneB 6A /ST473 y England 14 -9/ST9. Este es el primer estudio en determinar los mecanismos de resistencia a macrólidos en neumococos aislados de OMA en la Argentina y en describrir su relación genética. © 2013 Asociación Argentina de Microbiología. Publicado por Elsevier España, S.L. Todos los derechos reservados. 5 . We have to emphasize that applying the current breakpoints of CLSI, all isolates were susceptible to amoxicillin, which is the antibiotic recommended for the empirical treatment of AOM in our country. All isolates were susceptible to cefotaxime (MIC ≤ 1 μg/ml), and also to chloramphenicol, ofl oxacin and vancomycin when tested by the disk diffusion method, using the breakpoints recommended by the CLSI 5 . Resistance to erythromycin was recorded in 26 (20.6%) isolates of S. pneumoniae from AOM, mainly due to the presence of the mefA gene. Resistance to tetracycline and trimethoprim-sulfamethoxazole was observed in 13 (50%) and in 15 (57.7%) macrolide-resistant isolates, respectively.
PALABRAS CLAVE
Twenty of the 26 macrolide resistant isolates (76.9%) expressed the M-phenotype and were positive for the mefA gene, while 6 (23.1%) expressed the constitutive MLS Bphenotype. Five of them were positive for the ermB gene and one was positive for both genes ( 15 . None of the macrolideresistant isolates was found to be mefA and ermB negative. Other macrolide resistance mechanisms, such as mutations in the 23S rRNA or alterations in ribosomal proteins L4 and L22 have not been investigated.
Ten (10) clonal types (A to J) were defi ned by the SmaI-PFGE pattern. (fig.1 ). Seventeen isolates were grouped into three clones: clone A n:7, clone B n:6, and clone C n:4. The PFGE pattern of clones A and C were related to Sweden 15A -25 and England 14 -9 international clones defi ned in PMEN while clone B 6A was not related to any international clone. The remaining nine isolates were grouped into seven clones, of which only two were related to international clones: Spain 9V -3 and Poland 6B -20 (table 2) . In the study of Corso et al. referring to invasive infections, the emergency of erythromycin-resistant S. pneumoniae was principally due to the England 14 -9, Poland 6B -20 and Spain
9V
-3 international clones 6 , while in the present study both the Sweden 15A -25 and CloneB 6A clones were the major ones (table 2) . This could be the consequence of differences in spreading trends of clonal types producing AOM with respect to those producing invasive infections.
MLST was performed on clones which showed higher frequencies and on those that were associated with some international clones. (serotype 19F or 19A) . This clone has been described in Spain as a cause of meningitis and among multidrug-and ciprofl oxacin-resistant strains with different serotypes (14, 19A, 19F, and 23F) . In previous European studies 4 , the Sweden 15A -25 clone was the most frequently found clone among erythromycin-resistant pneumococci (www.mlst.net). The MLST database includes several ST63 isolates recovered from AOM in France. However, this database does not contain ST782 isolates from AOM. In the present study, the Sweden 15A -25 clone was also the most frequently found clone expressing serotype 14, probably due to a previous capsular switching event.
Alonso et al. studied pneumococcal isolates causing AOM in a region of Northern Spain between 1999 and 2010. The authors detected that clones ST63 and ST156 were only occasionally present in their region, the last one associated with ERY-susceptible isolates 1 . Bowers et al. reported the dominance of multidrug-resistant CC271 clones in macrolide-resistant pneumococci in Arizona, principally due to the dual genotype (mefE/ermB) 3 . Among the mef positive isolates, they found two belonging to the ST156 clone, one of them showing serotype 9V, similar to clone D isolates found in our study, and one isolate belonging to the ST162 clone. Among the ermB positive isolates, they found eight ST63 and two ST315, with serotype 6B, similar to clone I.
This study was carried out before the introduction of the PCV13 vaccine in our immunization schedule in 2012; therefore, it deserves to be repeated later, to evaluate the vaccine effectiveness and the possible spread of new S. pneumoniae clones in AOM.
Although macrolides or lincosamides are not fi rst-line antibiotics for the treatment of AOM, the knowledge about the prevalence of different macrolide-resistant mechanisms allowed us to assess and eventually predict their dissemination among pneumococci.
Although in our country we have data on the evolution of macrolide-resistant S. pneumoniae since 1995 from invasive infections and AOM 6 , this is the fi rst study assessing the mechanisms of macrolide resistance and genetic relatedness of S. pneumoniae isolated from pediatric patients suffering from AOM in Argentina.
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